A clinical study of transcranial ultrasound as an adjuvant therapy for progressive cerebral infarction

XIUJU GAO

Department of Neurology, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang 471003, P.R. China

Received December 6, 2012; Accepted January 24, 2013

DOI: 10.3892/etm.2013.965

Abstract. The present study aimed to investigate the clinical efficacy of transcranial ultrasound as an adjuvant therapy in combination with small doses of urokinase (UK) for the treatment of progressive cerebral infarction. Sixty-one eligible patients with progressive cerebral infarction were successively and randomly assigned into one of the following groups; 30 patients to the treatment group (transcranial ultrasound + small doses of UK) and 31 patients to the control group (single small doses of UK). Based on conventional therapy, patients in the treatment group received transcranial ultrasound. The neural function deficit scale and curative effect scores of the two groups were recorded before treatment and on the 7th and 14th days after treatment. No differences in the neural function deficit scale between the two groups was observed before treatment, however, on the 7th and 14th days after treatment, a significant decrease was evident in the treatment group (P<0.01). The overall response rate was 100% in the treatment group and 74.2% in the control group, with a significant difference (P<0.01). Transcranial ultrasound is able to contribute to the thrombolytic effects of UK and prevent the progression of thrombi, subsequently aiding the recovery of neural functions.

Introduction

Progressive ischemic stroke refers to the symptoms of neurological deficit present after ischemic stroke which demonstrate progressive aggravation and continue until further severe neurological deficits appear within 48 h (1). Progressive ischemic stroke accounts for 30% of all incidences of stroke and is associated with an increased rate of morbidity and mortality. Due to the difficulty in treating such cerebrovascular diseases (2), much attention has been devoted to this group of diseases by clinicians. In this study, we report 30 cases of clinical observation and analysis of transcranial ultrasound combined with small doses of urokinase (UK) for the treatment of progressive cerebral infarction.

Materials and methods

Clinical data. Sixty-one patients from The First Affiliated Hospital, Henan University of Science and Technology (Luoyang, China) were enrolled between October 2005 and October 2010. Each patient's diagnostic criteria met with the international diagnostic criteria of cerebral stroke (3). Patients were successively and randomly assigned into one of the following groups; 30 patients to the treatment group (small doses of UK + transcranial ultrasound) and 31 patients to the control group (single small doses of UK). No significant differences in age, onset time, complications and degree of nervous functional defects were observed between the two groups (P>0.05). Eligibility criteria for patients included: i) aged 40-75 years old; ii) clinical features were in accordance with internal carotid artery system cerebral infarction; iii) onset time was <72 h and the primary stroke symptoms of the nervous system and signs displayed continued progressive aggravation under doctor supervision and medical intervention; iv) cerebral hemorrhage was ruled out by cerebral CT/MRI; v) patients and/or their families provided written informed consent. This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of The First Affiliated Hospital, Henan University of Science and Technology.

Treatment. In the treatment group, 100 ml UK (250,000 units) + physiological saline was intravenously administered within 30 min. Simultaneously, transcranial ultrasound therapy combined with ultrasound through the transtemporal window of the lesion side was performed once a day for 20 min, for a total of 5 days. In the control group, 100 ml UK (250,000 units) + physiological saline was administered, and at the same time a therapeutic instrument was worn without any sound device, with the same treatment regimen as the treatment group. Both groups of patients were routinely administered drugs to promote blood circulation and remove blood stasis (such as Xuesaitong or Shuxuetong) and edaravone, a cerebral protec-
tive agent. Patients complicated with diabetes, hypertension or hyperlipidemia were administered the relevant treatment.

Observation. The two groups of patients routinely underwent cerebral CT/MRI, as well as examination of hemagglutination, blood routine, blood glucose, hepatonephric function and electrolyte levels before and after treatment. Patients were evaluated using the neural function deficit scale before treatment, and on the 7th and 14th days after treatment by neurologists.

Evaluation of efficacy. According to the latest diagnostic criteria for cerebral stroke modified in 2012, the degrees of clinical neurological deficit and the qualities of lives within each group of patients were scored and their efficacies determined (4): i) almost cured: the deficit score was decreased by 91-100%, with a grade 0 disability; ii) significantly improved: the deficit score was decreased by 46-90%, with a grade 1-3 disability; iii) improved: the deficit score was decreased by 18-45%, with independent life; iv) invalid: the deficit score was decreased by <17%; v) worse: the deficit score was increased by >18% or mortality.

Statistical analysis. The SPSS 10.0 software was used to analyze the data. The measurement data were measured by χ² inspection and are presented as mean ± SD.

Results

Neural function deficit scale. There was no significant difference in the neural function deficit scale between the two groups before treatment, however, a significant difference was evident after treatment. The Scandinavian Stroke Scale (SSS) rating decreased significantly on the 7th and 14th days after administration of treatment within the treatment group, with a significant difference before treatment compared with the control group (P<0.01, Table I).

Comparison of clinical efficacy. The overall response rate was 100% in the treatment group and 74.2% in the control group, with a significant difference (P<0.01, Table II).

Discussion

Progressive cerebral stroke is referred to as the increase of neurological deficit within several hours of the onset of disease, generally caused by the amplification of arterial thrombosis, with the exception of hematoma and edema (5). Around one-third of patients with stroke develop progressive stroke (6), which carries a significantly enhanced mortality and disability rate (7), causing an increasing number of difficulties in diagnosis and treatment and doctor-patient disputes. Hemodynamic pathogenesis is characterized by decreased perfusion in the ischemic zone causing collateral circulation insufficiency and progressive circulatory failure, followed by irreversible damage and penumbra expansion in the ischemic penumbra, which leads to the viability of brain cells in this area shortening and becoming unable to transfer information to other cells (8). The number and length of time that these type of cells exist is unstable. These cells are able to evolve into necrotic tissue or normal brain tissue. Therefore, this process may only be prevented after timely rescue of this penumbra (9). In previous years, ultra-early intravenous thrombolysis has achieved significant efficacies for the treatment of acute cerebral infarction (10), however, its time was limited to within 3-6 h. There were different time limits, treatment effects and safety views with respect to the application of UK thrombolysis in treatment of progressive cerebral stroke (11,12). A safe and effective method to extend the time window would prevent further progression in cerebral infarction patients occurring. Reducing the disability rate and improving patients’ quality of life is of great importance to clinicians.

In the present study, transcranial ultrasound therapy was used with an ultrasound instrument with a specific power and frequency (13). In 1976, Professor Lang Hongzhi of our

Table I. Neural function deficit scale before and after treatment in the two groups (mean ± SD).

| Group  | n  | Before treatment | 7 days after treatment | 14 days after treatment |
|--------|----|------------------|------------------------|------------------------|
| Treatment | 30 | 21.01±7.8        | 15.9±6.21              | 9.91±8.91*             |
| Control  | 31 | 20.82±9.53       | 20.12±9.53             | 18.3±9.58b             |

Compared with the control group, *P<0.01; compared with the treatment group, bP<0.01.

Table II. Comparison of efficacy between the two groups.

| Group  | n  | Almost cured | Significantly improved | Improved | No change | Significant efficacy | Overall response rate |
|--------|----|--------------|------------------------|----------|-----------|----------------------|-----------------------|
| Treatment | 30 | 12 (40)      | 16 (53.3)              | 2 (6.7)  | 0 (0)     | 28 (93.3)b          | 30 (100)b             |
| Control  | 31 | 5 (16.1)     | 10 (32.3)              | 8 (25.8) | 8 (25.8)  | 15 (48.4)           | 23 (74.2)             |

Compared with the control group, the significant efficacy aP<0.05; the overall response rate bP<0.01.
Transcranial ultrasound is capable of directly acting on the cerebral lesion site through the skull to promote migration of the thrombolytic drug to the blood clot by cleavage of cross-linked fibrin (19), subsequently aiding the thrombolytic effect. The instrument we used previously to perform ultrasound treatment was the type LHZ produced by the Kang Liya (Hong Kong Group) Biological Technology Co., Ltd. (Luoyang, China). It consisted of an ultrasonic generator, a treatment sound head and a fixed head frame. A 0.75-W/cm² pulsed ultrasound was generated with a 3-cm² sound head area and a 800-kHz ultrasonic frequency. The treatment was performed by fixing the sound head on the temporal window of the lesion side and coating the couplant on the surface of the sound head to ensure that the ultrasound penetrated through the skull. During intravenous infusion of UK, the ultrasonic treatment was administered for the same 20 min. In vitro tests, animal models and clinical studies have since confirmed that the ultrasound aids a unique biological effect of directly dissolving thrombi and enhancing the effects of thrombolytic drugs (20-22). Its mechanism of action may be summarized as cavitation, micro-flow effect, vibration causing mechanical action, thermal effects, sonochemistry action, ultrasonic penetration action, enhanced fibrinolytic activity, enhanced fiber drugs effect, shortened blood reperfusion time and reversal poisoning (23). The results of this study demonstrated that the neural function deficit scale of the transcranial ultrasound + small doses of UK group decreased significantly on the 7th and 14th days after treatment compared with the control group (P<0.01). This revealed that transcranial ultrasound contributes to the thrombolysis of UK and may thus be important for the treatment of progressive cerebral infarction by preventing thrombi from progressing and promoting the recovery of neural functions (23). In addition, transcranial ultrasound caused no pain, leading to a high patient compliance, with a quick curative effect and no cell damage caused. Owing to its mechanical effects, ultrasound is able to improve the metabolism levels of brain cells, subsequently aiding the recovery of brain cell function and preventing cell death. Followed by the improvement of brain function (25), the recovery of patient’s paralyzed limb, speech recovery, improved memory, which was worthy of clinical application.

References

1. Dreier JP: The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 17: 439-447, 2011.

2. Miedema I, Luijckx GJ and Uyttenboogaart M: Bleeding risk with ischemic stroke therapy. JAMA 308: 1318-1319, 2012.

3. Jamieson DG: Diagnosis of ischemic stroke. Am J Med 122 (Suppl 2): S14-S20, 2007.

4. Sobolewski P, Sledzińska M, Szczuciński W, Grzesik M, Sobota A and Hatalaska-Zerebiec R: Infranuclear thrombosis patients with acute ischemic stroke - the analysis of the 100 cases. Part II. Neuroimaging, the analysis of hemorrhagic complications and deaths. Przegl Lek 69: 242-246, 2012 (In Polish).

5. Kenei G, Lüthkef I.K, Alhassan M, et al: Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinus venous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 121: 1838-1847, 2010.

6. Stanley NC: Preventing recurrent ischemic stroke: a 3-step plan. J Fam Pract 54: 412-422, 2005.

7. Pikija S, Cvetko D, Malojić B, et al: A population-based prospective 24-month study of stroke: incidence and 30-day case-fatality rates of first-ever strokes in Croatia. Neuroepidemiology 38: 164-171, 2012.

8. Fisher M and Ginsberg M: Current concepts of the ischemic penumbra. Stroke 35: 2657-2658, 2004.

9. González RG: Imaging-guided acute ischemic stroke therapy: from ‘time is brain’ to ‘physiology is brain’. AJNR Am J Neuroradiol 27: 729-736, 2006.

10. Tirschwell DL, Coplin WM, Becker KJ, et al: Intra-arterial urokinase for acute ischemic stroke: factors associated with complications. Neurology 57: 1100-1103, 2001.

11. Lee RS, Ok YC, Lim JS, Lim BC, Cho KY and Lee MC: Outcome evaluation of intravenous infusion of urokinase for ischemic stroke. J Korean Med Sci 18: 52-56, 2002.

12. Macleod MR, Davis SM, Mitchell PJ, et al: Results of a multi-centre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 20: 12-17, 2005.

13. Levi CR, Selmes C and Chambers BR: Transcranial ultrasound-clinical applications in cerebral ischaemia. Australian Prescriber 24: 137-140, 2001.

14. Cerebrovascular Disease Treatment Group of the Third People’s Hospital of Luoyang City, Henan Province: Clinical analysis of 1005 cases of hemiplegia caused by ultrasound treatment of cerebrovascular disease. Chinese Journal of Internal Medicine 16: 220, 1976.

15. Trubestein R, Engel HR, Ezelf, et al: Thrombolysis by ultrasound. Clin Sci Mol Med 51: 697-698, 1976.

16. Mitragotri S, Blankscheidt D and Langer R: Transdermal drug delivery using low-frequency sonophoresis. Pharm Res 13: 411-420, 1996.

17. Daffertshofer M, Gass A, Ringleb P, et al: Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia. Stroke 36: 1441-1446, 2005.

18. Cherniavsky EA, Strakha IS, Adzerikho IE and Shkumatov VM: Frequency ultrasound-mediated thrombolysis in brain ischemia. Vasc Med 16: 220, 1976.

19. Lee RS, Ok YC, Lim JS, Lim BC, Cho KY and Lee MC: Outcome evaluation of intravenous infusion of urokinase for ischemic stroke. Korean J Med Sci 18: 52-56, 2002.

20. Macleod MR, Davis SM, Mitchell PJ, et al: Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 20: 12-17, 2005.

21. Levi CR, Selmes C and Chambers BR: Transcranial ultrasound-clinical applications in cerebral ischaemia. Australian Prescriber 24: 137-140, 2001.

22. Daffertshofer M, Gass A, Ringleb P, et al: Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia. Stroke 36: 1441-1446, 2005.

23. Hitchcock KE and Holland CK: Ultrasound-assisted thrombolysis for stroke therapy: better thrombus break-up with bubbles. Stroke 41: 505-503, 2010.

24. Francis CW and Suchkova VN: Ultrasound and thrombolysis. Stroke 41: S50-S53, 2010.

25. Zhang Z, Xue Y, Liu Y and Shang X: Additive effect of low-frequency ultrasound and endothelial monocyte-activating polypeptide II on blood-tumor barrier in rats with brain glioma. Neurosci Lett 481: 21-25, 2010.